KROS241220C45000
- 24.00
- 0.000.00%
Keros Therapeutics Newsroom
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Wedbush Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $84
Express News | Cantor Fitzgerald Reiterates Overweight on Keros Therapeutics
Piper Sandler Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $105
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $84 to $105
Keros Therapeutics Third Quarter 2024 Earnings: US$1.41 Loss per Share (Vs US$1.33 Loss in 3Q 2023)
Express News | HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target
A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $80 to $105
Keros Therapeutics: Strong Buy Rating Backed by Strategic Pipeline Progress and Favorable Trial Outcomes
Keros Therapeutics | 10-Q: Q3 2024 Earnings Report
Keros Therapeutics | 8-K: Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q3 Revenue $388,000
Express News | Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Press Release: Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Express News | Keros Therapeutics Q3 EPS USD -1.41
Wedbush Initiates Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $84
Jefferies Initiates Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $107
Express News | Keros Therapeutics To Present Three Abstracts At ASH Annual Meeting
Express News | Keros Therapeutics Inc : Wedbush Assumes Coverage With Outperform Rating; Target Price $84